Semaglutide: What It Is, What the Research Says, and What You Need to Know
An FDA-approved GLP-1 receptor agonist — the most-studied peptide for weight loss
Last updated: May 1, 2026
Educational purposes only. The information on this page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Research peptides are not FDA-approved for human therapeutic use unless explicitly stated. Always consult a licensed healthcare provider before using any compound.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of drugs that mimic the hormone GLP-1, which is naturally released after eating.
Developed by Novo Nordisk, semaglutide was first approved by the FDA in 2017 for type 2 diabetes (as Ozempic) and later at a higher dose for chronic weight management (as Wegovy) in 2021.
Unlike most peptides on this site, semaglutide has extensive clinical trial data from large-scale human studies involving tens of thousands of participants.
What Does the Research Say?
- The SUSTAIN clinical trial program showed semaglutide significantly reduced HbA1c in type 2 diabetes patients.
- The STEP trial program demonstrated an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial.
- SURMOUNT-3 trial showed up to 17.4% weight loss when combined with intensive behavioral intervention.
- Cardiovascular outcome trials (SELECT) showed 20% reduction in major cardiovascular events in overweight/obese patients without diabetes.
- Emerging research suggests potential benefits for fatty liver disease (MASH), kidney disease, and neurological conditions.
Research context: Animal studies showing positive effects do not guarantee the same results in humans. Human evidence strength varies significantly by peptide — see the Quick Stats sidebar for details.
Common Use Cases in Research
These reflect how researchers and research communities discuss this compound — not therapeutic recommendations.
- Type 2 diabetes management
- Chronic weight management
- Cardiovascular risk reduction
- Non-alcoholic fatty liver disease (MASH) research
How It Works (Mechanism of Action)
Activates GLP-1 receptors in the pancreas (increasing insulin secretion), brain (reducing appetite), and gut (slowing gastric emptying) — creating a powerful multi-system effect on blood sugar and body weight.
Reported Benefits & Risks
Reported Benefits
Reported Risks
What People Ask
What is semaglutide and how does it work?
Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1. It slows digestion, reduces appetite signals in the brain, and increases insulin release — resulting in lower blood sugar and significant weight loss.
Is semaglutide the same as Ozempic?
Yes. Ozempic, Wegovy, and Rybelsus all contain semaglutide as their active ingredient. The difference is dosage and formulation: Ozempic is weekly injection for diabetes, Wegovy is weekly injection at higher dose for weight loss, and Rybelsus is a daily oral tablet.
How much weight can you lose on semaglutide?
In the STEP 1 clinical trial, participants lost an average of 14.9% of body weight over 68 weeks. Individual results vary based on diet, exercise, and adherence.
Is semaglutide legal?
Yes, with a valid prescription from a licensed healthcare provider. Compounded semaglutide exists in a regulatory gray area — the FDA has taken action against some compounders.
Legal & Regulatory Status
FDA-Approved (Prescription)
FDA-approved prescription medication. Legal with a valid prescription. Compounded versions exist in a regulatory gray area.
Cited Research
Commonly Stacked With
Research Suppliers
Affiliate link below — we may earn a commission if you purchase. This does not influence our research coverage.
View Semaglutide Research Suppliers (affiliate link)